Use of PDE V inhibitors for improved fecundity in mammals
OwnerSimon Lempriere Westbrook, Johannes Fridrich Zanzingerinventors
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor for increasing fecundity in a mammal by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or for increasing milk productivity.
Claims25
A method of using a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor in the manufacture of a medicament for increasing fecundity in a mammal by (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny.
A method of treatment which comprises administering a therapeutically effective amount of a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (CGMP PDE V) inhibitor, to a female mammal, in order to increase fecundity, by one or more of (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny.
A method of increasing milk production in a female mammal by administration of a PDE V inhibitor to said mammal.
The method as in one of claims 24 or 6-7, in which the mammal is other than a human being.
The method as in one of claims 24 or 6-7, in which the mammal has a normal endometrial response.
A method of using a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor in the manufacture of a medicament for increasing the survival rate or growth rate of a neonate.
A method of treatment which comprises administering a therapeutically effective amount of a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V) inhibitor, to a female mammal, in order to increase the survival rate or growth rate of a neonate.
A method of increasing milk production in a female mammal which comprises treating said mammal with an effective amount of a PDE V inhibitor.
A veterinary formulation comprising a cyclic guanosine 3′,5′-monophosphate phosphodiesterase type five (cGMP PDE V ) inhibitor adapted for administration to a companion or livestock animal.
A pack comprising:
- a cyclic guanosine 3′, 5′-monophosphate phosphodiesterase type five (cGMP PDE V), optionally in a pharmaceutical or veterinary formulation;
- directions that would result in an increase in the fecundity, via (a) promoting the growth of an oocyte, zygote, blastocyst, embryo and/or fetus, (b) increasing the rate or probability of survival of an embryo and/or fetus and (c) increasing the birth weight of a progeny, or an increase in milk production, in a mammal;
- and
- packaging.
Dependencies are inferred from the claim text.